SESN Sesen Bio Inc.

1.1
0  0%
Previous Close 1.1
Open 1.11
Price To Book 7.33
Market Cap 111,392,486
Shares 101,265,896
Volume 533,730
Short Ratio
Av. Daily Volume 1,128,380

NewsSee all news

  1. Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H.C.

  2. Sesen Bio Announces CFO Transition as Company Drives Towards Anticipated Initiation of BLA Submission in 4Q 2019

    Company Appoints Monica Forbes as Chief Financial Officer and Kirstin Anderson as Principal Accounting Officer

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

BLA filing due 4Q 2019.
Vicinium
Non-muscle invasive bladder cancer (NMIBC)

Latest News

  1. Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H.C.

  2. Sesen Bio Announces CFO Transition as Company Drives Towards Anticipated Initiation of BLA Submission in 4Q 2019

    Company Appoints Monica Forbes as Chief Financial Officer and Kirstin Anderson as Principal Accounting Officer